P-glycoprotein expression and multidrug resistance in cutaneous T-cell lymphoma

Anand Jillella, J. R. Murren, K. K. Hamid, B. J. Longley, R. L. Edelson, D. L. Cooper

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Advanced-stage cutaneous T-cell lymphoma (CTCL) is generally resistant to standard chemotherapy. Because P-glycoprotein (P-gp) has been detected in other types of resistant solid tumors, leukemias, and lymphomas, we analyzed P-gp expression in CTCL. Twenty-seven patients with CTCL and circulating Sezary cells in the peripheral blood as observed on a peripheral smear treated at the Yale Photopheresis Center between 1987 and 1993 were identified Twenty-five of these patients had skin biopsies evaluated for expression of P-gp using JSB-1 (Accurate Chemical), MRK-16 (gift of T. Tsuruo), and UIC-2 (gift of E. Metchner). P-gp expression was considered present if immunoreactivity was noted with two of the three antibodies. Eighteen of 25 patients (72%) evaluated exhibited expression. The patients were treated with various combinations of drugs consisting of topical and systemic steroids, electron beam therapy, psoralens in combination with UV light A (PUVA), systemic chemotherapy, and photopheresis before testing the tissue for P-gp expression. Treatment with systemic chemotherapy in P-gp-positive patients produced responses in 3 and no responses in 11 patients (4 were lost to follow-up). Seven patients did not express P-gp: One patient responded to treatment, five did not respond, and one patient was lost to follow-up. These results demonstrate that P-gp is frequently expressed in CTCL. P-gp expression in our study was not a useful predictor of drug resistance.

Original languageEnglish (US)
Pages (from-to)609-613
Number of pages5
JournalCancer Investigation
Volume18
Issue number7
DOIs
StatePublished - Jan 1 2000

Fingerprint

Cutaneous T-Cell Lymphoma
Multiple Drug Resistance
P-Glycoprotein
Photopheresis
Gift Giving
Lost to Follow-Up
Drug Therapy
Drug Combinations
Ultraviolet Rays
Drug Resistance
Lymphoma
Leukemia
Therapeutics
Steroids
Electrons
Biopsy
Skin
Antibodies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Jillella, A., Murren, J. R., Hamid, K. K., Longley, B. J., Edelson, R. L., & Cooper, D. L. (2000). P-glycoprotein expression and multidrug resistance in cutaneous T-cell lymphoma. Cancer Investigation, 18(7), 609-613. https://doi.org/10.3109/07357900009032827

P-glycoprotein expression and multidrug resistance in cutaneous T-cell lymphoma. / Jillella, Anand; Murren, J. R.; Hamid, K. K.; Longley, B. J.; Edelson, R. L.; Cooper, D. L.

In: Cancer Investigation, Vol. 18, No. 7, 01.01.2000, p. 609-613.

Research output: Contribution to journalArticle

Jillella, A, Murren, JR, Hamid, KK, Longley, BJ, Edelson, RL & Cooper, DL 2000, 'P-glycoprotein expression and multidrug resistance in cutaneous T-cell lymphoma', Cancer Investigation, vol. 18, no. 7, pp. 609-613. https://doi.org/10.3109/07357900009032827
Jillella, Anand ; Murren, J. R. ; Hamid, K. K. ; Longley, B. J. ; Edelson, R. L. ; Cooper, D. L. / P-glycoprotein expression and multidrug resistance in cutaneous T-cell lymphoma. In: Cancer Investigation. 2000 ; Vol. 18, No. 7. pp. 609-613.
@article{911f0ba3b1864c96abf34aa3944d28f3,
title = "P-glycoprotein expression and multidrug resistance in cutaneous T-cell lymphoma",
abstract = "Advanced-stage cutaneous T-cell lymphoma (CTCL) is generally resistant to standard chemotherapy. Because P-glycoprotein (P-gp) has been detected in other types of resistant solid tumors, leukemias, and lymphomas, we analyzed P-gp expression in CTCL. Twenty-seven patients with CTCL and circulating Sezary cells in the peripheral blood as observed on a peripheral smear treated at the Yale Photopheresis Center between 1987 and 1993 were identified Twenty-five of these patients had skin biopsies evaluated for expression of P-gp using JSB-1 (Accurate Chemical), MRK-16 (gift of T. Tsuruo), and UIC-2 (gift of E. Metchner). P-gp expression was considered present if immunoreactivity was noted with two of the three antibodies. Eighteen of 25 patients (72{\%}) evaluated exhibited expression. The patients were treated with various combinations of drugs consisting of topical and systemic steroids, electron beam therapy, psoralens in combination with UV light A (PUVA), systemic chemotherapy, and photopheresis before testing the tissue for P-gp expression. Treatment with systemic chemotherapy in P-gp-positive patients produced responses in 3 and no responses in 11 patients (4 were lost to follow-up). Seven patients did not express P-gp: One patient responded to treatment, five did not respond, and one patient was lost to follow-up. These results demonstrate that P-gp is frequently expressed in CTCL. P-gp expression in our study was not a useful predictor of drug resistance.",
author = "Anand Jillella and Murren, {J. R.} and Hamid, {K. K.} and Longley, {B. J.} and Edelson, {R. L.} and Cooper, {D. L.}",
year = "2000",
month = "1",
day = "1",
doi = "10.3109/07357900009032827",
language = "English (US)",
volume = "18",
pages = "609--613",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - P-glycoprotein expression and multidrug resistance in cutaneous T-cell lymphoma

AU - Jillella, Anand

AU - Murren, J. R.

AU - Hamid, K. K.

AU - Longley, B. J.

AU - Edelson, R. L.

AU - Cooper, D. L.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Advanced-stage cutaneous T-cell lymphoma (CTCL) is generally resistant to standard chemotherapy. Because P-glycoprotein (P-gp) has been detected in other types of resistant solid tumors, leukemias, and lymphomas, we analyzed P-gp expression in CTCL. Twenty-seven patients with CTCL and circulating Sezary cells in the peripheral blood as observed on a peripheral smear treated at the Yale Photopheresis Center between 1987 and 1993 were identified Twenty-five of these patients had skin biopsies evaluated for expression of P-gp using JSB-1 (Accurate Chemical), MRK-16 (gift of T. Tsuruo), and UIC-2 (gift of E. Metchner). P-gp expression was considered present if immunoreactivity was noted with two of the three antibodies. Eighteen of 25 patients (72%) evaluated exhibited expression. The patients were treated with various combinations of drugs consisting of topical and systemic steroids, electron beam therapy, psoralens in combination with UV light A (PUVA), systemic chemotherapy, and photopheresis before testing the tissue for P-gp expression. Treatment with systemic chemotherapy in P-gp-positive patients produced responses in 3 and no responses in 11 patients (4 were lost to follow-up). Seven patients did not express P-gp: One patient responded to treatment, five did not respond, and one patient was lost to follow-up. These results demonstrate that P-gp is frequently expressed in CTCL. P-gp expression in our study was not a useful predictor of drug resistance.

AB - Advanced-stage cutaneous T-cell lymphoma (CTCL) is generally resistant to standard chemotherapy. Because P-glycoprotein (P-gp) has been detected in other types of resistant solid tumors, leukemias, and lymphomas, we analyzed P-gp expression in CTCL. Twenty-seven patients with CTCL and circulating Sezary cells in the peripheral blood as observed on a peripheral smear treated at the Yale Photopheresis Center between 1987 and 1993 were identified Twenty-five of these patients had skin biopsies evaluated for expression of P-gp using JSB-1 (Accurate Chemical), MRK-16 (gift of T. Tsuruo), and UIC-2 (gift of E. Metchner). P-gp expression was considered present if immunoreactivity was noted with two of the three antibodies. Eighteen of 25 patients (72%) evaluated exhibited expression. The patients were treated with various combinations of drugs consisting of topical and systemic steroids, electron beam therapy, psoralens in combination with UV light A (PUVA), systemic chemotherapy, and photopheresis before testing the tissue for P-gp expression. Treatment with systemic chemotherapy in P-gp-positive patients produced responses in 3 and no responses in 11 patients (4 were lost to follow-up). Seven patients did not express P-gp: One patient responded to treatment, five did not respond, and one patient was lost to follow-up. These results demonstrate that P-gp is frequently expressed in CTCL. P-gp expression in our study was not a useful predictor of drug resistance.

UR - http://www.scopus.com/inward/record.url?scp=0033810209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033810209&partnerID=8YFLogxK

U2 - 10.3109/07357900009032827

DO - 10.3109/07357900009032827

M3 - Article

VL - 18

SP - 609

EP - 613

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 7

ER -